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Effect of Standard RadiotherapyWith Cisplatin vs Accelerated
RadiotherapyWith Panitumumab in Locoregionally Advanced
Squamous Cell Head and Neck Carcinoma
A Randomized Clinical Trial
Lillian L. Siu, MD, FRCPC; John N.Waldron, MD; Bingshu E. Chen, PhD; Eric Winquist, MD; Jim R. Wright, MD; Abdenour Nabid, MD;
John H. Hay, MD; Jolie Ringash, MD; Geoffrey Liu, MD; Ana Johnson, PhD; George Shenouda, MD; Martin Chasen, MD; Andrew Pearce, MD;
James B. Butler, MD; Stephen Breen, PhD; Eric Xueyu Chen, MD; T. J. FitzGerald, MD; T. J. Childs, MD; Alexander Montenegro, MSc;
Brian O'Sullivan, MD;Wendy R. Parulekar, MD
IMPORTANCE The Canadian Cancer Trials Group study HN.6 is the largest randomized clinical
trial to date comparing the concurrent administration of anti–epidermal growth factor
receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard
chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the head and
neck (LA-SCCHN).
OBJECTIVE To compare progression-free survival (PFS) in patients with LA-SCCHN treated
with standard-fractionation RT plus high-dose cisplatin vs accelerated-fractionation RT plus
the anti-EGFR antibody panitumumab.
DESIGN, SETTING, AND PARTICIPANTS A randomized phase 3 clinical trial in 17 Canadian
centers. A total of 320 patients were randomized between December 2008 and November
2011.
INTERVENTIONS Patients with TanyN+M0 or T3-4N0M0 LA-SCCHNwere randomized 1:1 to
receive standard-fractionation RT (70 Gy/35 over 7 weeks) plus cisplatin at 100mg/m2
intravenous for 3 doses (arm A) vs accelerated-fractionation RT (70 Gy/35 over 6 weeks) plus
panitumumab at 9mg/kg intravenous for 3 doses (arm B).
MAIN OUTCOMES ANDMEASURES Primary end point was PFS. Due to an observed declining
event rate, the protocol was amended to a time-based analysis. Secondary end points
included overall survival, local and regional PFS, distant metastasis-free survival, quality of
life, adverse events, and safety.
RESULTS Of 320 patients randomized (268 [84%]male; median age, 56 years), 156 received
arm A and 159 arm B. A total of 93 PFS events occurred. By intention-to-treat, 2-year PFS was
73% (95% CI, 65%-79%) in arm A and 76% (95% CI, 68%-82%) in arm B (hazard ratio [HR],
0.95; 95% CI, 0.60-1.50; P = .83). The upper bound of the HR 95% CI exceeded the
prespecified noninferiority margin. Two-year overall survival was 85% (95% CI, 78%-90%) in
arm A and 88% (95% CI, 82%-92%) in arm B (HR, 0.89; 95% CI, 0.54-1.48; P = .66).
Incidence of any grade 3 to 5 nonhematologic adverse event was 88% in arm A and 92% in
arm B (P = .25).
CONCLUSIONS AND RELEVANCE With amedian follow-up of 46months, the PFS of
panitumumab plus accelerated-fractionation RT was not superior to cisplatin plus
standard-fractionation RT in LA-SCCHN and noninferiority was not proven. Despite having
negative results, HN.6 has contributed important data regarding disease control and toxic
effects of these treatment strategies.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00820248
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T reatment strategies for patients with locoregionally ad-vanced squamous cell carcinoma of the head and neck(LA-SCCHN) have continued to evolve over the past de-
cade,with theultimategoalofdevelopingnewapproaches that
can enhance the therapeutic index over existent regimens.
Based on the results of the meta-analysis of chemotherapy in
head and neck cancer (MACH-NC),1 cisplatin-based chemo-
therapyadministeredconcurrentlywith radiation therapy (RT)
remains the standard of care in LA-SCCHN. High-dose cis-
platin administeredat 100mg/m2 represents the standard sys-
temicagent in thecontrol armof randomizedclinical trials that
have recently been reported or completed accrual.2,3 In the
RadiationTherapyOncologyGroup(RTOG)0129trial,2 therewas
no statistically significant difference in efficacy outcomes and
in acute or late toxic effects between 3 cycles of high-dose cis-
platingivenwith standard-fractionationRT (SFX)vs2cyclesof
high-dose cisplatin given with accelerated-fractionation RT
(AFX). These results justify the choice of cisplatin plus SFX as
a control arm in phase 3 trials of LA-SCCHN testing new treat-
ment strategies, including in the present HN.6 study.
The concomitant administration of the anti–epidermal
growth factor receptor (EGFR) inhibitor monoclonal anti-
body cetuximab with RT led to improved survival compared
with RT alone in LA-SCCHN in the IMCL-9815 study.4 In sub-
group analysis, the application of AFX (concomitant boost)
demonstrated greater benefit from the addition of cetuximab
over SFX, with a hazard ratio (HR) of 0.64.4 With this obser-
vation,HN.6wasdesigned as a randomized, controlled phase
3 clinical trial with the primary objective of comparing the ef-
ficacy endpoint of progression-free survival (PFS) in patients
with LA-SCCHN treated with SFX plus high-dose cisplatin vs
AFX plus the anti-EGFR antibody panitumumab.
Methods
Study Design and Patients
HN.6 isamulticenter,open-label, randomizedcontrolledphase
3 studydesignedbyaprotocol committee that includedmem-
bers of Canadian Cancer Trials Group (study protocol in
Supplement 1). The institutional review boards of all partici-
pating institutions approved the protocol, and all partici-
pants gave written informed consent.
Selected eligibility criteria included histologically or cy-
tologically confirmed, locoregionally advanced squamous cell
carcinomaof theoral cavity, oropharynx, larynx,orhypophar-
ynx defined as T(any), N+,M0or T3-4, N0,M0. Other key eli-
gibility criteria included age 18 years or older; Eastern Coop-
erative Oncology Group (ECOG) performance status of 0 to 1;
andadequatebonemarrow, liver, andkidney functions.Acom-
plete list of all eligibility criteria in the study protocol is pro-
vided as eText in Supplement 2.
Randomization
Eligible patients were stratified according to T category
(T1-3 vs T4), nodal status (N0-1 vs N2 vs N3), RT delivery
modality (intensity-modulated RT vs 3-dimensional confor-
mal RT), and anatomic location (hypopharynx vs oral cavity
vs oropharynx vs larynx). Patients were randomly assigned
between December 30, 2008, and November 7, 2011, at a 1:1
ratio to the control regimen of SFX and cisplatin 100 (arm A)
or to the investigational regimen of AFX and panitumumab
(arm B). Randomization was performed by the Canadian
Cancer Trials Group Statistics and Operations Office with
the use of a minimization procedure that included stratifica-
tion factors and treatment center.5
Procedures
Radiation Therapy
All patients receivedRTwitheither concomitant cisplatin (arm
A) or panitumumab (arm B). In arm A, RTwas delivered once
daily to a total dose of 70 Gy in 35 fractions over 7weeks, and
inarmB, the same total dosewasdelivered in35 fractionsover
6weeksby introducing a twice-daily treatment onceperweek
for 5 weeks. Regions at risk of harboring microscopic disease
were treated to 56Gy in 35 fractions. Additional RTdetails are
provided as eText in Supplement 2.
Systemic Therapy
For patients randomly assigned to arm A, cisplatin was ad-
ministered intravenously at adoseof 100mg/m2ondays 1, 22,
and 43 of RT. Premedication and hydration were given in ac-
cordance with institutional standard. For patients randomly
assigned to arm B, panitumumab was administered intrave-
nously at a dose of 9mg/kg over 60 to 90minutes (plus ormi-
nus 15minutes) every3weeks, starting 1weekprior toRTstart,
on days −7, 15, and 36 of RT. All adverse events were graded
using the NCI Common Terminology Criteria for Adverse
Events, version 3.0.
Dosemodificationandresponseevaluationdetails arepro-
vided in eText in Supplement 2.
Statistical Analysis
The primary end point of this study was PFS, defined as the
time from randomization until the first objective observa-
tion of disease progression or death from any cause. Pro-
gression was defined by first event of the following: locore-
gional progression or recurrence; distant metastasis;
Key Points
Question Is the progression-free survival of patients with
locoregionally advanced squamous cell carcinoma of the head and
neck treated with accelerated-fractionation radiotherapy (RT) plus
the anti–epidermal growth factor receptor antibody panitumumab
better than that of those treated with standard-fractionation RT
plus high-dose cisplatin?
Findings In this randomized clinical trial of 320 patients, the
2-year progression-free survival of those receiving panitumumab
plus accelerated-fractionation RT was not superior to that of those
receiving cisplatin plus standard-fractionation RT. Noninferiority
was not proven.
Meaning Cisplatin plus standard-fractionation RT remains the
standard of care for patients with locoregionally advanced
squamous cell carcinoma of the head and neck.
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nonprotocol RT, chemotherapy, or biological therapy with-
out documentation of the site of failure; surgery of primary
site with tumor present/unknown; neck dissection with
tumor/unknown more than 15 weeks from end of RT; death
due to study cancer or from any other reason including
unknown causes.
The sample size for this study was originally calculated
to compare PFS between patients randomized to arm A vs
arm B. At the time of study initiation, information related to
the contribution of human papillomavirus (HPV) status in
LA-SCCHN was limited; thus, it was estimated that 2-year
PFS for arm A would be approximately 45%. To detect a
12.2% difference in 2-year PFS between 2 treatment arms,
which corresponded to an HR of 0.70, with 2-sided signifi-
cance level of .05 and 80% power, a total of 246 events in
PFS were required to trigger the final analysis. A total of 320
patients were required to observe 246 events.
A test for noninferiority of arm B to arm A was to be per-
formed if the primary analysis of superiority was not demon-
strated. Noninferiority of arm B to arm A would be claimed
when the upper limit of a 2-sided 95%confidence interval for
the HR was lower than or equal to 1.15.
Based on emerging knowledge about the favorable prog-
nosticeffectofHPV-positivestatus, aprotocol amendmentwas
implementedon approval by thedata safetymonitoring com-
mittee. The primary efficacy analysis was changed to a time-
based analysis with a clinical data cutoff date of October 31,
2014,with amedian follow-upduration thatwasdeemed suf-
ficient by theprotocol committee. Basedon the93PFS events
observedwith this cutoff, thepower for the superiority analy-
sis was 40%; the power for noninferiority analysis was 40%.
Secondary end points included (1) overall survival (OS),
(2) local and regional PFS, (3) distant metastasis-free
survival, (4) quality of life, and (5) adverse events and
safety. All patients who underwent randomization were
included in the baseline, PFS, and OS analyses by intention-
to-treat on the basis of the group to which they were
assigned. Further statistical analysis details are provided in
eText in Supplement 2.
Results
A total of 320 patients were randomized between December
2008andNovember 2011,with 160assigned to armAand 160
assigned to armB. Among them, 4 patients in armA and 1 pa-
tient in armBeither did not receive systemic therapy orwith-
drew their consents before the first dose of treatment. There-
fore, a total of 315 patients (156 on arm A and 159 on arm B)
were included in the treatment status and safety analyses
(Figure 1). Patients in both arms had similar baseline charac-
teristics (Table 1).Themedian follow-upwas46months (range,
0.1-64.3 months).
Efficacy
Atotal of 93PFSeventsoccurredat the timeof the clinical data
cutoff, 50 on arm A and 43 on arm B, with details about the
type of first event listed in eTable 1 in Supplement 2. The
Kaplan-Meier curve for the primary endpoint of PFS by treat-
ment arms is depicted in Figure 2. There was no statistically
significantdifferencebetween the2 treatmentarms (HR,0.95;
95% CI, 0.60-1.50 [arm B vs arm A], stratified log rank test
P = .83). The 2-year PFS for arm A was 73% (95% CI, 65%-
79%) and 76% for arm B (95%CI, 68%-82%). Because the up-
per bound of the HR 95% CI is 1.50, which exceeds the pre-
specifiednoninferioritymargin of 1.15, the trial doesnotmeet
thenoninferiority criterion in the comparisonof armB to arm
A in thePFSendpoint. Bymultivariable analysis, anatomic lo-
cation (oropharynxvs larynx;P = .001),ECOGperformancesta-
tus (P = .02), p16 status (P = .006), and T category (P < .001)
were significant predictors of PFS.
A subgroup analysis based on planned subgroups (ECOG
performance status,T category,Nstatus, primary site) andun-
planned subgroups (p16 status and smokinghistory) is shown
in eFigure in Supplement 2. No statistically significant differ-
ences in the relative effect of panitumumab plus AFX com-
pared with cisplatin plus SFX on PFS were seen across any of
the subgroups.
Among the 320 patients accrued to this trial, a total of 75
haddied at the timeof clinical data cutoff, 43 on armAand 32
on armB. The causes of deathwith details are summarized in
eTable 2 in Supplement 2. TheKaplan-Meier curve for the sec-
ondary end point of OS by treatment arms is depicted in
Figure 3. There was no statistically significant difference be-
tween the2 treatment arms (HR,0.89; 95%CI, 0.54-1.48 [arm
B vs armA], stratified log rank test P = .66). The 2-year OS for
arm A was 85% (95% CI, 78%-90%) and 88% for arm B (95%
CI, 82%-92%).
There were no statistically significant differences in any
of the other secondary efficacy endpoints: 2-year cumulative
incidenceof local recurrence forarmAwas4.5%(95%CI, 1.2%-
7.8%) and arm B was 7.0% (95% CI, 3.0%-10.9%), the cause-
specificHR,2.00 (95%CI,0.68-5.90 [armBvsarmA];P = .20);
2-year cumulative incidence of regional recurrence for armA
was 2.5% (95% CI, 0.1%-5.0%) and arm B was 3.8% (95% CI,
0.8%-6.8%), the cause-specific HR, 1.46 (95% CI, 0.30-4.97
[arm B vs arm A]; P = .64); and 2-year cumulative incidence
of distant recurrence for arm A was 10.2% (95% CI, 5.5%-
Figure 1. Consolidated Standards of Reporting Trials Diagram
320 Randomized
160 Randomized to arm A, cisplatin + 
standard-fractionation RT
156 Received cisplatin + 
standard-fractionation RT
as randomized
4 Received standard-
fractionation RT but no 
cisplatin or withdrew 
consent before first dose 
of treatment
1 Received accelerated-
fractionation RT but 
no panitumumab or 
withdrew consent before 
first dose of treatment
160 Included in the intention-
to-treat analysis
156 Included in safety analysis
160 Randomized to receive 
panitumumab + accelerated-
fractionation RT
159 Received panitumubab + 
accelerated-fractionation
RT as randomized
160 Included in the intention-
to-treat  analysis
159 Included in safety analysis
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15.0%) and armBwas 10.1% (95%CI, 5.4%-14.9%), the cause-
specific HR, 1.01 (95%CI, 0.49-2.11 [armB vs armA]; P = .97).
Safety
Grade 3 or higher adverse events of interest of any attribution
are summarized in Table 2. All-grade on-treatment adverse
events of any attribution are provided in eTable 3 in
Supplement 2. In general, arm A study treatment led to in-
creasedototoxic effects such ashearing loss and tinnitus, gas-
trointestinal toxic effects such as nausea, vomiting, and de-
hydration, renal toxic effects, and weight loss. Arm B study
treatment resulted in a greater incidence of skin toxic effects
and grade 3 or highermucositis. High-grade hematologic and
biochemical adverse events were uncommon in both study
arms, with slightly increased frequencies observed in bone
marrow toxic effects and electrolyte disturbances such as hy-
pokalemia,hypomagnesemia,andhyponatremia inarmAcom-
paredwith armB.At6months after completionof study treat-
ment, 9 of 143 patients who had functional oral intake status
available were feeding tube dependent for feeding in arm A
(6%) and 19 of 147 patients (13%)were tube dependent in arm
B. At 12months after completion of study treatment, feeding
tubedependency rateswere3%and8%, respectively, for arms
A and B. There were 3 treatment-related deaths on study
(eTable 2 in Supplement 2).
Treatment Delivery
Systemic treatment dose intensities and RT delivery data are
provided in eTable 4 in Supplement 2. Only 99 of 156 (63%)
patients in arm A received all 3 cycles of cisplatin whereas
144 of 159 (91%) patients in arm B received all 3 cycles of
panitumumab. The mean (SD) cumulative dose was 245.8
(56.4) mg/m2 (range, 92.4-306.6 mg/m2) of cisplatin in arm A
and 26.5 (2.99) mg/kg (range, 16.3-32.8 mg/kg) of panitu-
Table 1. Patient Characteristics
Characteristic
Value
Arm A:
Cisplatin + SFX
(n = 160)
Arm B:
Panitumumab + AFX
(n = 160)
Total
(N = 320)
Sex, No. (%)
Female 26 (16) 26 (16) 52 (16)
Male 134 (84) 134 (84) 268 (84)
Age
Median, y 56 56.5 56
≥60 y, No. (%) 58 (36) 52 (33) 110 (34)
ECOG performance status, No. (%)
0 111 (69) 115 (72) 226 (71)
1 49 (31) 45 (28) 94 (29)
Anatomic location of primary, No. (%)
Oral cavity 2 (1) 5 (3) 7 (2)
Oropharynx 132 (83) 127 (79) 259 (81)
Larynx 18 (11) 17 (11) 35 (11)
Hypopharynx 8 (5) 11 (7) 19 (6)
T Category, No. (%)
T1-3 134 (84) 131 (82) 265 (83)
T4 26 (16) 29 (18) 55 (17)
N Status, No. (%)
N0-1 22 (14) 23 (14) 45 (14)
N2 128 (80) 129 (81) 257 (80)
N3 10 (6) 8 (5) 18 (6)
Smoking history, No. (%)
None 47 (29) 44 (27) 91 (28)
≤10 Pack-years 15 (9) 22 (14) 37 (12)
>10 Pack-years 95 (59) 92 (58) 187 (58)
Missing 3 (2) 2 (1) 5 (2)
HPV Status (p16 by IHC) for oropharyngeal cancer
only, No. (%)
(n = 132) (n = 127) (n = 259)
Negative 25 (19) 16 (13) 41 (16)
Positive 86 (65) 90 (71) 176 (68)
Missing 21 (16) 21 (16) 42 (16)
RT delivery modality, No. (%)
IMRT 157 (98) 158 (99) 315 (98)
3D CRT 3 (2) 2 (1) 5 (2)
Abbreviations:
AFX, accelerated-fractionation
radiation therapy; ECOG, Eastern
Cooperative Oncology Group;
HPV, human papillomavirus;
IHC, immunohistochemistry;
IMRT, intensity-modulated radiation
therapy; RT, radiation therapy;
SFX, standard-fractionation radiation
therapy; 3D CRT, 3-dimensional
conformal radiation therapy.
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mumab in arm B, suggesting that overall systemic treatment
dose intensity was greater in arm B than arm A. Adherence
to RT delivery was high, with completion of 70 Gy in 98% of
patients in both arms, with mean RT duration of 49 (range,
43-64) days in arm A and 42 (range, 32-51) days in arm B.
Radiotherapy interruptions due to toxic effects were
observed in 2 (1.3%) and 3 (1.9%) in arms A and B, respec-
tively. At final retrospective external review by Quality
Assurance Review Center, treatment adherence was deemed
appropriate in 150 (96%) and 157 (99%) of plans in arms A
and B, respectively.
Quality of Life
Detailedquality-of-life analysesare reported ina separatepub-
lication. There was no statistically significant difference be-
tween the2 studyarms in theprimaryquality-of-life endpoint
in this study,definedas themedian changeof6points ormore
in the overall score from baseline to 1 year on the Functional
Assessment of Cancer Therapy–Head and Neck question-
naire (arm A = −1.70, arm B = −4.81; P = .19).
Discussion
In this randomized controlled phase 3 trial, superiority or
noninferiority in PFS of panitumumab plus AFX compared
with cisplatin plus SFX in LA-SCCHNwas not demonstrated.
There were also no statistically significant differences
between the 2 treatment arms with respect to secondary
end points. There are several potential reasons to explain
these outcomes.
First, 2 randomized phase 2 trials investigating panitu-
mumab and RT in combination using either a chemo-
additive approach (CONCERT-1)6 or a chemo-sparing
approach (CONCERT-2)7 in LA-SCCHN have recently been
published, both reporting negative results in their primary
end point of 2-year locoregional control. These results are
aligned with the findings of HN.6 and may be attributable to
the use of panitumumab (a fully human immunoglobulin G2
antibody) instead of other anti-EGFR monoclonal antibod-
ies, such as cetuximab (a chimeric immunoglobulin G1
Figure 3. Overall Survival (OS)
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Figure 2. Progression-free Survival (PFS)
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antibody) that can elicit antibody-dependent cell-mediated
cytotoxicity as a mechanism of antitumor activity. Currently,
cetuximab is the only anti-EGFR antibody approved by the
US Food and Drug Administration for the treatment of
LA-SCCHN in combination with RT.8 Furthermore, cetux-
imab demonstrated an improvement in OS when combined
with platinum and fluorouracil (Erbitux in First-Line Treat-
ment of Recurrent or Metastatic Head and Neck Cancer
[EXTREME] trial) in the recurrent or metastatic SCCHN
setting,9 whereas panitumumab given with the same che-
motherapy doublet (Study of Panitumumab Efficacy in
Patients with Recurrent and/or Metastatic Head and Neck
Cancer [SPECTRUM] trial) did not achieve a statistically sig-
nificant OS benefit compared with chemotherapy alone.10
While the difference between the EXTREME and SPECTRUM
trials may not be solely due to the anti-EGFR antibody under
evaluation, as variations in the study populations and trial
designs exist, it is unlikely that a well-powered, direct head-
to-head comparison of these 2 agents will ever be per-
formed, in contrast to the case of advanced colorectal can-
cer, in which more than 1000 patients were enrolled to
confirm noninferiority.11
Second, HN6 was designed in the era when evidence for
the biological significance of HPV status in SCCHN was just
emerging. As such, it did not specifically include or exclude
participants based on their tumoral HPV or p16 status,
unlike RTOG 1016 (NCT01302834) or the Trans-Tasman
RadiationOncologyGroup (TROG) study 12.01 (NCT01855451),
which are both phase 3 trials comparing chemoradiotherapy
vs bioradiotherapy in HPV-related oropharyngeal cancer.
RTOG 1016 compared AFX plus cisplatin against AFX plus
cetuximab with an OS end point, whereas TROG 12.01
compared SFX plus panitumumab against SFX with weekly
cisplatin, with a primary end point of symptom severity from
baseline to week 20 after treatment. If the addition of
anti-EGFRmonoclonal antibody to RT portends a differential
effect in LA-SCCHNbased onHPV status, then theunselected
patient population of HN.6 may have diluted such an effect.
Although subgroup analysis by p16 status was not significant
in HN.6, there are known limitations with small-subset
evaluations. Retrospective analysis of the IMCL-9815 study
showedthat theadditionofcetuximabtoRTbenefittedpatients
with locoregionallyadvancedoropharyngeal cancer regardless
of p16 status, although the magnitude of the gain seemed to
be more pronounced among patients with p16-positive
tumors.12 It is also notable that there were differences in the
patientpopulationsofCONCERT-1,CONCERT-2, andHN.6 that
might render their direct comparisons incongruous.6,7 In
the CONCERT trials, patients with oropharyngeal cancer
madeupapproximately 48% to53%of the studypopulations,
while this anatomical subgroup accounted for 81% in HN.6.
Among patients with oropharyngeal cancer, the proportions
ofp16-positive tumorswere28%, 16%,and68%inCONCERT-1,
CONCERT-2, andHN.6, respectively.Given thenearly identical
2-year PFS between the 2 arms in HN.6 (73% vs 76%;
HR,0.95; 95%CI, 0.60-1.50;P = .83), in contrast to thehigher
2-year PFS in the chemoradiotherapy arm compared to
bioradiotherapyarminCONCERT-2 (62%vs41%;HR, 1.73;95%
CI, 1.07-2.81;P = .03),7 it is possible that bioradiotherapymay
be a suitable alternative to chemoradiotherapy in p16-
positive oropharyngeal cancers, a question that will be more
definitively addressed as the results of RTOG 1016 become
available.
Last, due to the low event rate, HN.6 lacked the power to
detect the differences in PFS outcome as originally designed
both for superiorityandnoninferiority.RTOG1016hasasample
sizenearly3 times thatofHN.6,but isdesignedasaclassicnon-
inferiority study with a 7.6%-point lower boundary for OS at
5 years for the inferiormarginof the cetuximabarm. It is plau-
sible that a small difference exists in efficacy between the 2
treatment arms in HN.6 but was not detected due to the lim-
ited sample size.
ThedesignofHN.6 involvedanexperimental armthatdif-
fered from the control arm with respect to the RT and sys-
temic therapy components, making it difficult to assess the
relative contribution of each variable had the trial outcome
been positive. However, the intention was to combine EGFR
inhibition (panitumumab)with themost optimalRT fraction-
ation scheme using AFX as previously reported,4,12 and
to assess the relative efficacy of 2 different combination
therapies, similar to the approach in RTOG 0129.2
Table 2. Selected Grade 3-5 Adverse Event (AE) Summary
Adverse Event
Patients With Grade 3-5 AE, No. (%)
Arm A:
Cisplatin + SFX
(n = 156)
Arm B:
Panitumumab + AFX
(n = 159)
Nonhematologic
Acne 0 17 (11)
Dehydration 15 (10) 8 (5)
Dermatitis (any cause) 22 (14) 52 (33)
Dysphagia 50 (32) 49 (31)
Fatigue 17 (11) 16 (10)
Hearing loss 18 (12) 1 (1)
Mucositis (oral cavity) 60 (38) 82 (52)
Nausea 16 (10) 9 (6)
Pain (throat/pharynx/larynx) 10 (6) 14 (9)
Renal failure 5 (3) 1 (1)
Tinnitus 9 (6) 0
Vomiting 12 (8) 2 (1)
Weight loss 4 (3) 0
Any 138 (88) 146 (92)
Hematologic
Hemoglobin decrease 13 (8) 3 (2)
Febrile neutropenia 7 (4) 0
Neutropenia 30 (19) 2 (1)
Platelet decrease 0 0
Biochemical
Hypokalemia 23 (15) 13 (8)
Hypomagnesemia 5 (3) 2 (1)
Hyponatremia 28 (18) 8 (5)
Abbreviations: AFX, accelerated-fractionation radiation therapy;
SFX, standard-fractionation radiation therapy.
Radiotherapy and Cisplatin vs Accelerated Radiotherapy and Panitumumab Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology February 2017 Volume 3, Number 2 225
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/oncology/936042/ by a University of Massachusetts User  on 04/07/2017
Copyright 2017 American Medical Association. All rights reserved.
Conclusions
Despite the inability to demonstrate superiority or noninfe-
riority of bioradiotherapy over chemoradiotherapy, HN.6
has contributed important outcome data associated with
these treatment strategies. It offered a valuable opportunity
to standardize intensity-modulated RT and ensure quality of
RT techniques across its participating sites. It also provided
a platform for detailed assessment of quality of life, swal-
lowing symptoms, and physiologic swallowing function
among patients with LA-SCCHN receiving concurrent com-
bined therapy, which will be an invaluable source of data to
characterize the impact of disease and treatment from the
patient perspective. A clinically well-annotated repository
of tumor and blood-based biospecimens has been collected
as part of the correlative science objective of this study,
which will be germane to hypotheses-generated transla-
tional research to better elucidate the role of EGFR inhibi-
tion in this disease.
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